Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter TB regimens could simplify treatment

NCT ID NCT07668479

Disease control Sponsor: Public Union "Kazakhstan Association of Phthisiopulmonologists" Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether shorter, rifapentine-based treatments for tuberculosis and latent TB are safe and effective in real-world settings in Kazakhstan. It will follow 350 adults, including those with HIV, comparing a 4-month regimen to the standard 6-month one for active TB, and a 1-month regimen for latent TB. The goal is to see if these shorter options can improve cure rates and reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rifapentine (combined with isoniazid, moxifloxacin, pyrazinamide, or ethambutol)
What this could lead to
If successful, this could show that shorter TB treatments work as well as standard ones, making it easier for patients to complete therapy and reducing the spread of TB.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the shorter regimens could still occur, and findings may not apply outside Kazakhstan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years and older with drug-susceptible tuberculosis or tuberculosis infection, including people living with and without HIV, enrolled at tuberculosis facilities in four regions of Kazakhstan.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: FOR DS-TB COHORTS (2HPMZ/2HPM and 2HRZE/4HR): * Age 18 years or older * Bacteriologically confirmed drug-susceptible pulmonary tuberculosis * Newly diagnosed, not previously treated (or treated less than 1 month) * Willing and able to provide written informed consent * Residing in one of the four pilot regions of Kazakhstan FOR TBI COHORT (1HP): * Age 18 years or older * Diagnosed with tuberculosis infection * No evidence of active tuberculosis disease * Willing and able to provide written informed consent * Residing in one of the four pilot regions of Kazakhstan Exclusion Criteria: FOR DS-TB COHORTS: * Confirmed or suspected drug-resistant tuberculosis (rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant tuberculosis (MDR-TB)) * Extrapulmonary tuberculosis as the sole manifestation * Pregnancy or breastfeeding at time of enrollment * Severe hepatic impairment (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \>3x upper limit of normal) * Known hypersensitivity to rifapentine, isoniazid, moxifloxacin, or pyrazinamide * corrected QT interval (QTc) interval \>500 ms on baseline electrocardiogram (ECG) * Currently receiving medications with significant interactions contraindicated with study regimens FOR TBI COHORT: * Active tuberculosis disease * Previous treatment for TB or TBI within the past 2 years * Pregnancy at time of enrollment * Severe hepatic impairment * Known hypersensitivity to rifapentine or isoniazid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis Tuberculosis infection, latent Tuberculosis, pulmonary, drug sensitive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.